Walgreens, a retail pharmacy chain, has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services, to strengthen decentralized clinical trials through the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program.
The partnership, valued at up to USD 100 million, will utilize Walgreens' clinical trial ecosystem to validate, pilot, and implement new products, technologies, and approaches for remote clinical trials during public health emergencies. This collaboration aims to make clinical research more accessible and representative of the US population, addressing current challenges such as low enrollment rates and limited participant diversity.
Walgreens' platform has reached over five million potential trial participants since 2022, demonstrating its effectiveness in patient recruitment. The partnership also builds on a previous collaboration between Walgreens and BARDA for a Phase IV observational Covid-19 trial to enhance US public health preparedness.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.